Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labeled Pembrolizumab Biosimilar - Anti-PD1 mAb - Research Grade |
---|---|
Source | DrugBank DB09037 |
Species | Human |
Expression system | Mammalian cells |
Molecular weight | 149kDa |
Purity | >90% |
Buffer | PBS pH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | Pembrolizumab |
Reference | PX-TA1007-SIL |
Related Products | PX-P4116 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG4 |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2 |
Isotopic Enrichment | 99% |
Stability | 1 year |
Formula | C6504H10004N1716O2036S46 |
Pembrolizumab is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body’s immune cells and some cancer cells, known as PD-1/PD-L1. This product is for research use only.
Related products
Reviews
Il n’y a pas encore d’avis.